Replimune Group, Inc. priced an underwritten public offering of 9,701,490 shares of common stock at $12.06 per share and pre-funded warrants for 2,736,340 additional shares at $12.0599 each. The transaction generates approximately $150 million in gross proceeds and $140.5 million in net proceeds after deducting underwriting discounts and offering expenses. Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. served as bookrunning managers. Closing is expected on August 11, 2026. Replimune Group, Inc. operates in the biotechnology industry, developing novel oncolytic immunotherapies for cancer treatment.
